Topics

Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer

19:52 EST 14 Jan 2020 | Pharmaceutical Business Review

As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates

The post Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer appeared first on Pharmaceutical Business review.

Original Article: Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer

NEXT ARTICLE

More From BioPortfolio on "Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...